Celebrity Diagnoses Spur Immediate Public Response
When high-profile figures publicly discuss their prostate cancer, the public health impact can be immediate. The media coverage raises awareness, prompting more men to seek information or medical advice. A recent example is media personality Jeremy Clarkson, who last week revealed his prostate cancer diagnosis. This was followed by a spike in men visiting Prostate Cancer UK's website to check their risk.
Other Notable Figures and Their Disclosures
Other high-profile men to disclose their diagnoses include author and broadcaster Stephen Fry, actor Ben Stiller, and former US president Joe Biden. Such publicity can reduce stigma and encourage conversations about symptoms, but it also has downsides, skewing perception of prostate cancer and who might benefit from testing and treatment.
The Trade-Off of Raising Awareness
Prostate cancer remains a major cause of cancer death among men. Increased attention following a public figure's disclosure can help reduce stigma around men's health and encourage conversations about symptoms. It can draw attention to aggressive or metastatic prostate cancer, prompting men who have never considered prostate health to seek information or discuss risk with a doctor. This is particularly helpful for men at higher risk.
However, most prostate cancers are not immediately life-threatening. Many men "die with prostate cancer, not from it," as some cancers grow so slowly they would never cause symptoms or shorten life. Media coverage has tended to exaggerate the benefits of screening and not fully explain risks and uncertainties. Celebrities are often viewed as trusted role models, and their personal experiences can shape public understanding in ways not fully aligned with scientific evidence. This may lead to over-screening, detection of extremely slow-growing cancers, and rushed decisions for immediate treatment that isn't always needed.
The Screening Debate: PSA Test Benefits and Harms
The main screening test is the prostate-specific antigen (PSA) blood test. It can detect cancers earlier but also identify false positives, when high levels turn out not to be due to prostate cancer. The test can also identify dormant tumours that will never cause harm. Unnecessary investigations or treatments can expose men to urinary, bowel, and sexual side effects.
Prostate cancer screening using the PSA test remains widely debated. A recent Cochrane review, which draws together the best available evidence, found that PSA-based screening likely reduces deaths from prostate cancer at a population level. However, the number of men who may benefit is small. The review estimated that screening 1,000 men would lead to one to two fewer prostate cancer deaths in the long term (11–23 years of follow-up) compared to not screening. Against this benefit, screening would mean 16 extra men diagnosed and treated among 1,000, some of whom would be overdiagnosed and overtreated for cancers that would not cause harm if left undetected.
The review did not conclude every man should have a PSA test. It found that while screening may reduce the chance of dying from prostate cancer, it can also lead to unnecessary tests and treatment. The balance of benefit to potential harms can be easily shifted by overly frequent testing of men unlikely to benefit or insufficiently frequent testing of men at high risk, with considerable costs to individuals and the health system.
Updated Guidelines Emphasize Shared Decision-Making
The new evidence is leading to updated clinical guidelines in many countries, including Australia and the United Kingdom. The revised draft Australian guidelines are likely to recommend that men who ask for testing must be informed of the benefits and harms first, with targeted recommendations for specific groups. The UK National Screening Committee recommends a more targeted offering for men aged 45–61 who have particular genetic variants (BRCA2 gene) with a family history of breast, ovarian, pancreatic, or prostate cancer. Both guidelines support a shared decision-making approach, where men discuss their age, family history, overall health, personal values, and tolerance for uncertainty with their health-care provider before deciding whether to have a PSA test. Both advise against widespread, population-wide screening.
Conclusion: Informed Conversations Over Panic
Decisions around prostate cancer screening are complex. Men must weigh both benefits and harms from PSA testing through to potential treatments. The latest evidence suggests PSA screening can save some lives, but the benefit is modest and comes with important trade-offs. Celebrity stories should be a starting point for informed conversations. Public awareness is valuable when it leads to informed decision-making, not when it replaces it.
